Pomegra
Natera Stock Falls 16.6% After Wider Quarterly Loss
Why is Natera stock down today?
Natera (NTRA) stock fell 16.6% to $303.50 on Friday after an earnings miss, as a much wider quarterly loss outweighed a 34% revenue jump and a raised outlook.
Key numbers
| Q3 revenue | $794.0M+34.1% YoY; est. about $702M |
|---|---|
| Q3 net loss | $59.9M$0.42/share vs $0.17–$0.27 expected |
| 2026 revenue outlook | $3.005–3.035B+$140M at midpoint |
| Share price | $303.50-16.6% from $363.76 |
| Gross margin | 64.7%vs 64.9% a year ago |
What happened
Natera (NTRA) stock fell 16.6% to $303.50 on Friday after an earnings miss, as a much wider quarterly loss outweighed a 34% revenue jump and a raised outlook. Sales rose to $794 million from $592 million a year ago, and the company lifted its 2026 sales forecast (guidance) to $3.005–$3.035 billion. But it lost $59.9 million, or 42 cents a share, far more than analysts expected, because it spent more on research, sales teams and its business serving drugmakers. CEO Steve Chapman also stepped down, and Solomon Moshkevich took over.
Why it matters
Natera, which makes genetic blood tests, shows that fast growth is not always enough for investors when a company is still losing money. Sales are climbing and the forecast went up, yet the stock dropped because losses were bigger than expected and the top boss changed at the same time. Other cancer and gene-testing companies, including Guardant Health and GRAIL, also fell after their own reports.
Who this affects
- MarketbearishMedium impact
- Investors in loss-making testing stocks face selling pressure, a negative.
- CompanybearishHigh impact
- Natera shareholders lost value; a new CEO adds uncertainty.
- CompetitorsbearishMedium impact
- Guardant Health and GRAIL also fell after their own reports.
- IndustrymixedMedium impact
- Strong demand continues, but profit worries weigh on the sector.
Natera vs Guardant Health, GRAIL
How we got here
GRAIL reports a Q3 revenue miss and its shares drop in after-hours trading.
Natera reports Q3 after the market closes and names Solomon Moshkevich CEO.
Natera closes at $363.76, before the earnings report.
Natera shares fall 16.6% to $303.50 in Friday trading.
What to watch
- Whether new CEO Moshkevich can steer Natera toward its $6 billion revenue goal for 2029.2029-12-31
- Whether Natera's losses narrow as spending on research and sales teams continues.Q1 2027
- Whether Natera delivers on its raised 2026 revenue outlook of $3.005–$3.035 billion.Q4 2026
Educational content only. Not investment advice.
More briefsAll briefs →
Five9 Stock Sinks 20% After Weak Q4 Guidance
Five9 (FIVN) shares slid as it guided Q4 profit to $0.90 a share against $0.99 expected, and bought Level AI.
TSMC Stock Falls 4.7% on AI Regulation Fears
TSMC (2330.TW) opened limit-down as Taiwan's Taiex fell 12.2% this week, its worst since 1991.
2-Year Treasury Yield Drops to 4.47% as Rate-Hike Odds Fall
December Fed hike odds fell to about 69% from 83% even as Cleveland Fed's Hammack urged a restrictive stance.